Introducing the GLP-1 and Metabolic Health Registry

The most complete picture of GLP-1 therapy ever assembled, built entirely from patients themselves.

GLP-1 therapies are one of the biggest shifts in medicine in a generation. Millions of people are starting them and indications are expanding quickly. The new reality is that the population taking them looks a lot less like the population that was ever studied in a trial.

Today, we're introducing the GLP-1 and Metabolic Health Registry. The best real-world dataset built to see these therapies the way patients actually experience them. A continuous, cross-system record that gives a deep, years long view of the real patient journey.

6,000+ patients. 1,800+ GLP-1 initiators with follow-up. Growing every day.

Here's what that depth is already revealing, and why it matters for the people making decisions about these therapies right now.

What this means for HEOR and Medical Affairs

HEOR teams get comorbidity-stratified outcomes data they can put directly into cost-effectiveness models, payer value dossiers, and formulary submissions. Persistence, response, and utilization, tracked over years, mapped to the real clinical complexity of the patients using these drugs.

Medical Affairs teams get a stronger evidence base for publications and the conversations clinicians are already having about how these therapies perform once patients leave the trial and enter real life. It's a foundation for engaging KOLs, supporting label expansion, and answering the hard questions with real data instead of extrapolation.

Where it shows up

• Payer and formulary strategy. Evidence on how coverage disruptions and treatment interruptions shape outcomes, ready for reimbursement and formulary conversations.
• Label expansion. Outcomes across comorbidity subgroups that trials were never built to enroll at scale.
• Commercial strategy. A clear read on which patient profiles respond best in the real world, informing where and how a therapy gets positioned.
• Post-marketing surveillance. Multi-year signals on persistence, discontinuation, and switching.
• Medical education. Real patient context for congress presentations, publications, and clinician-facing content.

What the data is already showing

Three numbers are reshaping how we think about who responds to GLP-1 therapy:

• ‍81% of high-comorbidity patients (Elixhauser 10+) achieved 5% or greater weight loss, compared to 54% of low-comorbidity patients. (p < .001)‍
• 75%+ of enrolled patients carry high comorbidity burdens: anxiety, depression, chronic pain.

Persistence holds steady across comorbidity burden. The most clinically complex patients stay on therapy at the same rate as everyone else.

Data captured per patient

• Weight, BMI, and percent weight change pre- and post-GLP-1 initiation over time
• Labs: HbA1c, lipid panels, blood pressure, timestamped with LOINC codes
• Reasons for GLP-1 initiation, discontinuation, and side effect management
• Comorbidity burden across chronic, behavioral, and pain conditions
• Lifestyle habits (diet, exercise) as documented by the clinician
• Healthcare utilization: outpatient, inpatient, ED, telemedicine
• Patient-reported symptom tracking and sociodemographic data (income, race, ethnicity)
• Sponsor-specific ePRO surveys: waist/hip ratio, body composition, dietary routines
• Additional unstructured data elements available on request

What the records show, from one patient in the registry.

Meet Sandra (named changed), she's in her mid-forties and her record spans seven years and six health systems: nearly 5,000 clinical documents. Three GLP-1 agents, tried in sequence, with the full reasoning for every switch documented alongside it. A fourteen-month insurance denial and appeal. More than twenty emergency department visits in a single year, before she found a therapy that finally held.

Then, in early 2026, a routine gallbladder surgery required a short pause in her tirzepatide. Three weeks later, her outpatient provider wrote the note that explains everything: her binge eating was back. That single sentence, buried in a clinical note, connects a surgical protocol to a behavioral relapse across two different care settings and a gap of three weeks. It's the kind of connection that only surfaces when a record follows one person continuously, for years, everywhere they go.

Why we built this

Metabolic health is moving faster than the evidence supporting it. The patients now using GLP-1 therapies carry more comorbidities, see more providers, and navigate more coverage changes than the populations these drugs were originally studied in. The industry needs an evidence base built for that reality: continuous, cross-system, and detailed enough to explain what happened to a patient and why it happened.

That's what we built. Every record in the registry starts with a patient choosing to share their own health history. From there, it follows them everywhere: every provider, every payer, every care setting, for decades.

"For too long, we have operated within a system that overlooks the sickest patients, despite them having the most to gain," said Shashi Shankar, Co-Founder and CEO of Novellia. "Tired of being overlooked, these patients have turned to Novellia as a trusted source of truth. In doing so, they are also helping life sciences companies understand how therapies perform in the real world. With Novellia, teams can see how treatment changes, coverage disruptions, and other real-world factors shape the patient experience over time. That level of visibility has never existed before, and the GLP-1 market needs it now more than ever."

How we build it

Patients come first, literally. People use Novellia to find and unify their own health records, then choose to contribute that de-identified and anonymous history to research. Because the patient is the source of authorization, their record travels with them: across every hospital, every insurer, every care setting they ever use.

Each record blends structured data (diagnoses, prescriptions, labs, claims) with the unstructured clinical notes where most of the real reasoning lives. Averaging more than 20 years per patient, that depth is what lets Novellia trace a single person's path through diagnosis, treatment, coverage change, discontinuation, and re-initiation, across as many health systems as their life actually touched.

The numbers

• 6,000+ patients enrolled, growing daily
• 1,800+ GLP-1 initiators with follow-up
• 20+ years of continuous history per patient, on average
• 100x more data per patient than a standard research dataset
• 81% vs. 54% weight loss response, high- vs. low-comorbidity patients
• 75%+ of patients carry high comorbidity burdens
• Persistence holds steady regardless of comorbidity burden
• Research presented at ASCO and SABCS-AACR

Let's talk

Get a deep dive in the data with our team to see how the registry can support your study needs.